Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context
Background: Health technology assessment (HTA) is a process evaluating various aspects of healthcare technologies to support evidence-based decisions. Benign prostatic hyperplasia (BPH) is a common condition among aging men, significantly affecting QoL. Traditional treatments like transurethral res...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2025-07-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/3401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849303742883561472 |
|---|---|
| author | Agostino Fortunato Eugenio Di Brino Michele Basile Debora Antonini Filippo Rumi |
| author_facet | Agostino Fortunato Eugenio Di Brino Michele Basile Debora Antonini Filippo Rumi |
| author_sort | Agostino Fortunato |
| collection | DOAJ |
| description |
Background: Health technology assessment (HTA) is a process evaluating various aspects of healthcare technologies to support evidence-based decisions. Benign prostatic hyperplasia (BPH) is a common condition among aging men, significantly affecting QoL. Traditional treatments like transurethral resection of the prostate (TURP) and Holmium Laser Enucleation (HoLEP) are effective but often associated with complications and sexual dysfunction.
The Prostatic Urethral Lift (PUL) system (UroLift) offers a minimally invasive alternative, preserving sexual function
and ensuring faster recovery.
Methods: Using the EUnetHTA Core Model 3.0, UroLift was evaluated across nine domains, combining a systematic
review of literature, expert consultation, and real-world evidence. A Budget Impact Model (BIM) simulated
treatment pathways over five years, comparing UroLift with TURP and HoLEP.
Results: As the analysis shows, despite the higher initial acquisition cost, UroLift generates savings for the NHS in
all the years considered within the analysis. Specifically, savings are derived from the lower incidence of adverse
events and complications, both post-operative and in the long term, implying lower inpatient costs and less use of
human resources. As anticipated, savings begin in the first year with a differential between the two scenarios considered at 57,747.40 and peak in the fifth year with savings of approximately €1.35 million, for a total estimated
savings over the considered time horizon, considering the market shares, of €3,154,997.63.
Conclusions: UroLift demonstrates clinical efficacy, faster recovery, and sexual function preservation while generating cost savings, supporting its integration into BPH management pathways in Italy.
|
| format | Article |
| id | doaj-art-74f831f19f3d44d7a5dc0ae9364f7649 |
| institution | Kabale University |
| issn | 2284-2403 2283-5733 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj-art-74f831f19f3d44d7a5dc0ae9364f76492025-08-20T03:55:59ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332025-07-0112110.33393/grhta.2025.3401Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian contextAgostino Fortunato0Eugenio Di Brino1Michele Basile2Debora Antonini3Filippo Rumi4Alta Scuola di Economia e Management dei Sistemi Sanitari (Altems), Università Cattolica del Sacro Cuore, Roma - ItalyAlta Scuola di Economia e Management dei Sistemi Sanitari (Altems), Università Cattolica del Sacro Cuore, Roma - ItalyAlta Scuola di Economia e Management dei Sistemi Sanitari (Altems), Università Cattolica del Sacro Cuore, Roma - ItalyAlta Scuola di Economia e Management dei Sistemi Sanitari (Altems), Università Cattolica del Sacro Cuore, Roma - ItalyAlta Scuola di Economia e Management dei Sistemi Sanitari (Altems), Università Cattolica del Sacro Cuore, Roma - Italy Background: Health technology assessment (HTA) is a process evaluating various aspects of healthcare technologies to support evidence-based decisions. Benign prostatic hyperplasia (BPH) is a common condition among aging men, significantly affecting QoL. Traditional treatments like transurethral resection of the prostate (TURP) and Holmium Laser Enucleation (HoLEP) are effective but often associated with complications and sexual dysfunction. The Prostatic Urethral Lift (PUL) system (UroLift) offers a minimally invasive alternative, preserving sexual function and ensuring faster recovery. Methods: Using the EUnetHTA Core Model 3.0, UroLift was evaluated across nine domains, combining a systematic review of literature, expert consultation, and real-world evidence. A Budget Impact Model (BIM) simulated treatment pathways over five years, comparing UroLift with TURP and HoLEP. Results: As the analysis shows, despite the higher initial acquisition cost, UroLift generates savings for the NHS in all the years considered within the analysis. Specifically, savings are derived from the lower incidence of adverse events and complications, both post-operative and in the long term, implying lower inpatient costs and less use of human resources. As anticipated, savings begin in the first year with a differential between the two scenarios considered at 57,747.40 and peak in the fifth year with savings of approximately €1.35 million, for a total estimated savings over the considered time horizon, considering the market shares, of €3,154,997.63. Conclusions: UroLift demonstrates clinical efficacy, faster recovery, and sexual function preservation while generating cost savings, supporting its integration into BPH management pathways in Italy. https://journals.aboutscience.eu/index.php/grhta/article/view/3401Benign prostatic hyperplasiaBudget impact modelHTAUrolift |
| spellingShingle | Agostino Fortunato Eugenio Di Brino Michele Basile Debora Antonini Filippo Rumi Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context Global & Regional Health Technology Assessment Benign prostatic hyperplasia Budget impact model HTA Urolift |
| title | Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context |
| title_full | Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context |
| title_fullStr | Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context |
| title_full_unstemmed | Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context |
| title_short | Health technology assessment (HTA) of prostatic urethral lift (PUL) for the treatment of benign prostatic hyperplasia (BPH) in the Italian context |
| title_sort | health technology assessment hta of prostatic urethral lift pul for the treatment of benign prostatic hyperplasia bph in the italian context |
| topic | Benign prostatic hyperplasia Budget impact model HTA Urolift |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/3401 |
| work_keys_str_mv | AT agostinofortunato healthtechnologyassessmenthtaofprostaticurethralliftpulforthetreatmentofbenignprostatichyperplasiabphintheitaliancontext AT eugeniodibrino healthtechnologyassessmenthtaofprostaticurethralliftpulforthetreatmentofbenignprostatichyperplasiabphintheitaliancontext AT michelebasile healthtechnologyassessmenthtaofprostaticurethralliftpulforthetreatmentofbenignprostatichyperplasiabphintheitaliancontext AT deboraantonini healthtechnologyassessmenthtaofprostaticurethralliftpulforthetreatmentofbenignprostatichyperplasiabphintheitaliancontext AT filipporumi healthtechnologyassessmenthtaofprostaticurethralliftpulforthetreatmentofbenignprostatichyperplasiabphintheitaliancontext |